SEC Comment Letter for PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — Sep 19, 2014
PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: Sept. 19, 2014 · CIK: 0001095981 · Accession: 0000000000-14-047242
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-34375
Letter
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE September 19, 2014 Via E -mail Marc Hedrick President & Chief Executive Officer Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121
Re: Cytori Therapeutics, Inc. Form 10 -Q for the Quarterly Period Ended June 30, 2014 Filed August 11, 2014 File No. 001-34375
Dear Mr. Hedrick :
We have reviewed your response letter dated September 1 9, 2014 and filing s and have the following comment . In our comment , we may ask you to provide us with information so we may better understand your disclosure.
Please respond to this letter within ten business days by providing the requested information or by advising us when you will provide the requested response. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.
After reviewing the information you provide in response to this comment , we may have additional comments.
Form 10 -Q for the Quarterly Period Ended June 30, 2014
Item 1. Financial Statements
Note 7. Revenue Recognition, page 9
1. We note your response to prior comment 6. Please tell us if the change in timing for revenue recognition until cash is collected is applicable to all new customers or only to new customers within Japan. If the new timing applies to all new customers, pl ease tell us the basis for the change in timing for customers outside Japan.
Marc Hedrick Cytori Therapeutics, Inc. September 19, 2014 Page 2
You may contact Kristin Lochhead , Senior Accountant, at (202) 551 -3664 or Kate Tillan , Assistant Chief Accountant, at (202) 55 1-3604 if you have questions regarding comments on t he financial statements and related matters. Please contact me at (202) 551-3671 with any other questions.
Sincerely,
/s/ Kate Tillan for
Show Raw Text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
DIVISION OF
CORPORATION FINANCE
September 19, 2014
Via E -mail
Marc Hedrick
President & Chief Executive Officer
Cytori Therapeutics, Inc.
3020 Callan Road
San Diego, CA 92121
Re: Cytori Therapeutics, Inc.
Form 10 -Q for the Quarterly Period Ended June 30, 2014
Filed August 11, 2014
File No. 001-34375
Dear Mr. Hedrick :
We have reviewed your response letter dated September 1 9, 2014 and filing s and
have the following comment . In our comment , we may ask you to provide us with
information so we may better understand your disclosure.
Please respond to this letter within ten business days by providing the requested
information or by advising us when you will provide the requested response. If you do
not believe our comments apply to your facts and circumstances, please tell us why in
your response.
After reviewing the information you provide in response to this comment , we may
have additional comments.
Form 10 -Q for the Quarterly Period Ended June 30, 2014
Item 1. Financial Statements
Note 7. Revenue Recognition, page 9
1. We note your response to prior comment 6. Please tell us if the change in timing
for revenue recognition until cash is collected is applicable to all new customers
or only to new customers within Japan. If the new timing applies to all new
customers, pl ease tell us the basis for the change in timing for customers outside
Japan.
Marc Hedrick
Cytori Therapeutics, Inc.
September 19, 2014
Page 2
You may contact Kristin Lochhead , Senior Accountant, at (202) 551 -3664 or Kate
Tillan , Assistant Chief Accountant, at (202) 55 1-3604 if you have questions regarding
comments on t he financial statements and related matters. Please contact me at (202)
551-3671 with any other questions.
Sincerely,
/s/ Kate Tillan for
Martin James
Senior Assistant Chief Accountant
cc: Mr. Tiago Girão (via E -mail)